|Bid||5.99 x 800|
|Ask||6.00 x 900|
|Day's Range||5.93 - 6.12|
|52 Week Range||4.98 - 37.27|
|Beta (3Y Monthly)||1.67|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Clovis Oncology, Inc. (CLVS) announced today the pricing of $250 million aggregate principal amount of its 4.50% convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Clovis Oncology has also granted to the initial purchasers a 13-day option to purchase up to $37.5 million aggregate principal amount of additional notes on the same terms and conditions. The holders of the notes may convert their notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date at an initial conversion rate of 137.2213 shares of Clovis Oncology’s common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $7.29 per share of common stock.
Clovis Oncology, Inc. (CLVS) announced today that, subject to market and other conditions, it intends to offer $225 million aggregate principal amount of its convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Clovis Oncology also expects to grant the initial purchasers a 13-day option to purchase up to $33.75 million aggregate principal amount of additional notes on the same terms and conditions. Clovis Oncology will not have the right to redeem the notes prior to their maturity.
Clovis Oncology, Inc. will announce its second quarter 2019 financial results on Thursday, August 1, 2019, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.
“I am very pleased to announce that Ginger Graham is assuming the role of our Board Chair at Clovis Oncology. As an active Clovis board member for six years, Ginger is extremely familiar with our organization and will bring her tremendous expertise as a healthcare executive to her elevated role as Board Chair,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology.
BOULDER, Colo.-- -- In exploratory analysis of ARIEL3 data, Rubraca significantly improved clinically meaningful endpoints including chemotherapy free interval and PFS on next therapy line for women with advanced ovarian cancer in maintenance treatment setting Updated Rubraca safety profile was consistent with the safety profile previously observed in ARIEL3 TRITON2 findings show that tumor tissue ...
Quality-adjusted progression free survival and quality-adjusted time without cancer related symptoms or toxicity demonstrate the benefit of Rubraca maintenance t
Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, genomic data from phase 2 TRITON2 clinical trial, and the designs of other ongoing rucaparib trials
BOULDER, Colo.-- -- $33.1M in Rubraca ® global sales for the first quarter of 2018 Updated data on 52 patients with BRCA-mutant mCRPC provided to FDA; RECIST response rate highly consistent with that shown at ESMO 2018 Targeting late 2019 for supplemental NDA filing for BRCA-mutant advanced prostate cancer; data update expected at Fall 2019 medical meeting Clovis-sponsored combination studies of lucitanib ...
Clovis Oncology, Inc. (CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch Healthcare Conference 2019 on Tuesday, May 14, 2019 at 2:20 PM Pacific Time. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.
Clovis Oncology, Inc. (CLVS) today announced that it has entered into an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG Sixth Street Partners to reimburse Clovis’ costs and expenses related to the ATHENA clinical trial. ATHENA is Clovis Oncology’s largest clinical trial, with a planned target enrollment of 1000 patients across more than 270 sites in at least 25 countries.
Clovis Oncology, Inc. will announce its first quarter 2019 financial results on Tuesday, May 7, 2019, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.
BOULDER, Colo.-- -- Interim data from an investigator-initiated study in first-line maintenance setting for advanced pancreatic cancer suggest that Rubraca provides disease control with no new safety signals in 19 evaluable platinum-sensitive patients with germline BRCA1, germline or somatic BRCA2, or germline PALB2 mutations Clovis is evaluating a potential clinical and regulatory path forward for ...
Accepted abstracts highlight data from a phase 2 investigator-initiated trial of Rubraca® in pancreatic cancer, clinical and nonclinical research of Rubraca in multiple
BOULDER, Colo.-- -- Exploratory analyses of ARIEL3 Rubraca data in recurrent ovarian cancer presented in oral plenary and poster sessions Maintenance treatment with Rubraca improved median progression-free survival and reduced the risk of progression vs placebo regardless of age subgroup Maintenance treatment with Rubraca significantly improved PFS and reduced the risk of progression vs placebo regardless ...
Clovis Oncology, Inc. (CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 at 11:15 a.m. Eastern time. The conference will be held at the Loews Miami Beach Hotel in Miami. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
BOULDER, Colo. & MUNICH-- -- Rubraca ® offers a new monotherapy maintenance treatment option for eligible women with platinum-sensitive relapsed ovarian cancer, regardless of BRCA status Rucaparib provided statistically significant improvement in progression-free survival versus placebo in all ovarian cancer patients studied Some patients with residual disease at ARIEL3 study entry who were treated ...
BOULDER, Colo.-- -- 2018 Rubraca ® U.S. sales totaled $95.4M, including $30.4M for the fourth quarter of 2018 Rubraca EU approval granted January 2019 for ovarian cancer maintenance treatment indication; launch in Germany to initiate on this Friday, March 1 Robust Clovis-sponsored Rubraca development program in place; enrollment ongoing for clinical studies in ovarian, prostate and bladder cancers ...
NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Clovis Oncology, Inc. (NASDAQ: CLVS ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 at ...
Clovis Oncology, Inc. (CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern time. The conference will be held at the Lotte New York Palace in New York City. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.
DUBLIN and BOULDER, Colo., Feb. 19, 2019 /PRNewswire/ -- Alkermes plc (ALKS) and Clovis Oncology, Inc. (CLVS) today announced that the companies have entered into a research collaboration to evaluate ALKS 4230, Alkermes' investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with rucaparib, Clovis' marketed PARP inhibitor, and lucitanib, Clovis' investigational tyrosine kinase inhibitor. The collaboration will explore the potential anti-cancer effects of both treatment combinations in preclinical models across multiple tumor types.
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Clovis Oncology, Inc. will announce its fourth quarter/fiscal year 2018 financial results on Tuesday, February 26, 2019, before the open of the U.S. financial markets.
BOULDER, Colo.-- -- Rubraca ® offers a new monotherapy option in Europe for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy, regardless of BRCA status Positive data from the phase 3 ARIEL3 clinical trial supported this expanded indication making Rubraca ...
TORONTO, ON / ACCESSWIRE / January 10, 2019 / The Wealthy Biotech Trader (or ''WBT''), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device stocks making news and subsequent market moves, would like to update investors on several breakthroughs in cancer therapies hitting the market. Stock investors have soured on biotech companies over the past several months, as demonstrated by the SPDR S&P Biotech ETF (XBI), off 30% since June, and the NYSE Biotechnology Index (NYSE:NBI), which has dropped from 3500 in mid-2018 to just under 3000 at year-end, and a host of their component companies and others in addition. One of those is Propanc Biopharma, Inc. (OTCQB:PPCB), an Australian biotech company with strong management and technology that has the potential to help millions of cancer patients worldwide.